Early adoption of BRCA1/2 testing: Who and why

Genetics in Medicine

Volumn 5, Issue 2, 2003, Pages 92-98

  Armstrong, Katrina ^a,b,c   Weiner, Janet ^a,c   Weber, Barbara ^a,b   Asch, David A ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

BRCA1 2 genetic testing; Diffusion; Utilization

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; AWARENESS; BREAST CANCER; CANCER DIAGNOSIS; COHORT ANALYSIS; COMPLEX FORMATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIFFUSION; FEMALE; GENETIC ASSOCIATION; GENETIC COMPATIBILITY; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH CARE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MASS COMMUNICATION; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; OVARY CANCER; PATIENT REFERRAL; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

EMPIRICAL APPROACH; GENETICS AND REPRODUCTION;

DECISION MAKING; DIFFUSION OF INNOVATION; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC SCREENING; HUMANS; PATIENT PARTICIPATION;

EID: 0042405009     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000056829.76915.2A     Document Type: Article

References (33)

1. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792 (erratum in Nature 1996;379:749).
2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
3. Kolata G. Breaking ranks, lab offers test to asess risk of breast cancer. New York Times April 1, 1996:A1.
4. Struewing J, Lerman C, Kase R, Giambarresi T, Tucker M. Anticipated uptake and inpact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 1995;4:169-173.
5. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994;12:843-850.
6. Craufurd D, Dodge A, Kerzin-Storrar L, Harris R. Uptake of presymptomatic testing for Huntington's disease. Lancet 1989;2:603-605.
7. Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ et al. Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet 1994;55:626-637.
8. Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2000;9:1251-1254.
9. Biesecker B, Ishibe N, Hadley D, et al. Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 2000;93:257-263.
10. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes. JAMA 1996;275:1885-1929.
11. Chaliki H, Loader S, Levenkron J, Logan-Young W, Hall W, Rowley P. Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 1995;85:1133-1135.
12. Rogers E. Diffusion of Innovations, 4th ed. New York: Free Press, 1995.
13. Tornatzky L, Klein K. Innovation characteristics and innovation adoption implementation: A meta-analysis of findings. IEEE Trans Eng 1982;6:28-45.
14. Pankratz M, Hallfors D, Cho H. Measuring perceptions of innovation adoption: The diffusion of a federal drug policy. Health Educ Res 2002;17:315-326.
15. Schubart J, Einbinder J. Evaluation of a data warehouse in an academic health sciences center. Int J Med Inf 2000;60:319-333.
16. Ferrence R. Diffusion theory and drug use. Addiction 2001;96:165-173.
17. Ferrence R. Using diffusion theory in health promotion: The case of tobacco. Can J Public Health 2002;87(suppl 2):S24-S27.
18. Mesters I, Meertens R. Monitoring the dissemination of an educational protocol on pediatric asthma in family practice: A test of associations between dissemination variables. Health Educ Behav 1999;26:103-120.
19. Gingiss P, Gottlieb N, Brink S. Measuring cognitive characteristics associated with adoption and implementation of health innovation in schools. Am J Health Promot 1994;8:294-301.
20. Elford J, Sherr L, Bolding G, Serle F, Maguire M. Peer-led HIV prevention among gay men in London: Process evaluation. AIDS Care 2002;14:351-360.
21. Smith M, DiClemente R. STAND: A peer educator training curriculum for sexual risk reducation in the rural south. Prev Med 2000;30:441-449.
22. Bartholemew L, Czyzewski D, Swant P, McCormick L, Parcel G. Maximizing the impact of the cystic fibrosis family education program: Factors related to program diffusion. Fam Community Health 2000;22:27-47.
23. Worden J, Solomon L, Flynn B, McVety D, Dorwaldt A, Geller B. Community-based promotion of breast screening using small group education. J Public Health Manag Pract 1999;5:54-62.
24. Roberts-Gray C, Solomon T, Gottlieb N, Kelsey E. Heart Partners: A strategy for promoting effective diffusion of school health promotion programs. J Sch Health 1998;68:106-110.
25. Couch F, DeShano M, Blackwood M, Weber B. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-1415.
26. Frank T, Manley S, Olopade O, Cummings S, Barber J. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16:2417-2425.
27. Moore G, Benbasat I. Development of an instrument to measure the perceptions of adopting an information technology innovation. Inf Syst Res 1991;2:192-222.
28. Goldsmith R, Hofacker C. Measuring consumer innovativeness. J Acad Mark Sci 1991;19:209-221.
29. Agarwal R, Prasad J. A conceptual and operational definition of personal innovativeness in the domain of information technology. Inf Syst Res 1998;9:204-215.
30. Breslow N, Day N. Statistical Methods in Cancer Research. Lyon: International Agency for Research on Cancer, 1994.
31. Rogers E. Diffusion of preventive innovations. Addict Behav 2002;27:989-993.
32. Peterson EA, Milliron KJ, Lewis KE, Good SD, Merajver SD. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002;11:79-87.
33. Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 2002;14:19-26.